Sentences with phrase «chronic myelogenous leukemia»

[8] p230 is usually associated with chronic myelogenous leukemia associated with neutrophilia and thrombocytosis.

In 1972, she identified a genetic glitch in chronic myelogenous leukemia cells — a swap of genes she called chromosomal translocation — that resulted in the uncontrolled cell growth of cancer.

Brian J. Druker, M.D. Oregon Health Sciences University Mechanism - based therapy for chronic myelogenous leukemia

The team has shown that the microenvironment that controls hematopoietic stem cells can be targeted for the treatment of a set of disorders called myeloproliferative neoplasias, the most prominent of which are chronic myelomonocytic leukemia (CMML), juvenile myelomonocytic leukemia (JMML), and atypical chronic myelogenous leukemia (CML).

It is used to treat chronic phase and accelerated phase Philadelphia chromosome positive chronic myelogenous leukemia (Ph + CML).

Currently no treatment option is available for five percent of patients suffering from chronic myelogenous leukemia, since they have developed resistance to conventional medications.

A research group in Japan and in Korea has found a novel nutrient uptake process that maintains the activity of murine chronic myelogenous leukemia (CML) stem cells.

«How do harmful chronic myelogenous leukemia stem cells obtain their nutrients?.»

Since the first targeted cancer therapy to treat chronic myelogenous leukemia became available in 2001, there has been an explosion in genomic technology.

The drug imatinib mesylate (Gleevec) is shown to be effective against chronic myelogenous leukemia (CML).

Adenine causes cell cycle arrest and autophagy of chronic myelogenous leukemia K562 cells via AMP - activated protein kinase signaling.

Such fusions have been implicated in other cancers, notably chronic myelogenous leukemia (CML).

Already, a few examples exist — blood tests for hereditary colon cancer; the design of Herceptin, a breast cancer drug; and Gleevec, a drug used in chronic myelogenous leukemia — in which the identification of gene alterations translated into clinical applications.

About Blog The blog is about journey of Leukemia Survivor diagnosed with Chronic myelogenous leukemia (CML).

Investigators report that the six - month study of nilotinib, a treatment for chronic myelogenous leukemia or CML, produced benefit for all study patients who completed the trial (11 of 12), with 11 patients reporting meaningful clinical improvements.

Her research has recently shown that a signaling pathway dubbed «hedgehog» is important not only for normal development of stem cells but also for the growth of cancer cells in chronic myelogenous leukemia.

For example, chronic myelogenous leukemia is caused by overproduction of certain white blood cells in the bone marrow.

In both acute and chronic myelogenous leukemia, immature white blood cells in the bone marrow multiply out of control.

This knowledge laid the foundation for the targeted cancer treatment revolution inaugurated by imatinib (Gleevec ®), which has made another blood cancer, chronic myelogenous leukemia, a controllable, chronic disease for many patients.

Chronic myelogenous leukemia (CML) is a human disease associated with a consistent chromosomal translocation that results in sequences from the c - abl locus on chromosome 9 being fused to sequences in a breakpoint cluster region (bcr) on chromosome 22.

New treatment strategies to overcome drug resistance in chronic myelogenous leukemia and other cancers will come from the detailed structure of the enzyme Abl.

• Subject has BCR - ABL - positive leukemia (chronic myelogenous leukemia in blast crisis).

An exciting development in rational anticancer drug design is Gleevac, a drug that acts on a protein unique to the defective white blood cells in chronic myelogenous leukemia and on a related protein in a rare form of gastrointestinal cancer.

Immunodeficiency and chronic myelogenous leukemia - like syndrome in mice with a targeted mutation of the ICSBP gene.

City of Hope researchers may have discovered a more effective treatment for patients with chronic myelogenous leukemia (CML) according to a study published today in Nature Medicine.

During this time, she worked in the laboratory setting with MAPK signaling pathway in Chronic Myelogenous Leukemia, for which she received an American Society of Clinical Oncology (ASCO) Young Investigator Award.

In support of the first tenet, both chronic myelogenous leukemia (11) and acute myelogenous leukemia (12) seem to have arisen from the committed progenitor cells that have acquired self - renewing capabilities.

This work, and that of colleagues Brian Druker and Novartis, led to the development of the kinase inhibitor imatinib (Gleevec) as primary therapy for chronic myelogenous leukemia (CML), and the discovery that imatinib resistance is caused by BCR - ABL kinase domain mutations.

About Blog I started this blog to keep my friends and family informed about my progress with Chronic Myelogenous Leukemia (CML).

We have also documented that the same mutations are responsible for the development of certain cancers in humans and dogs, such as the BCR - ABL translocation in chronic myelogenous leukemia.